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Abstract. The liver can be affected by a wide range
of therapeutic and environmental chemicals and here
we want to provide a summary of the complex effects
of alcohol, cannabinoids and nicotine on liver func-
tion. Alcohol is the most important agent that pro-
duces liver injury, manifesting as alcoholic fatty liver
disease. In addition, it is one of the main etiologic agents
for hepatocellular carcinoma development. Studies re-
viewed in this article regarding cannabinoids, show that
∆9-THC does not produce any harmful effects on the
liver, while cannabidiol has hepatoprotective effects in
ischemia/reperfusion and alcohol-induced liver injuries.
The liver is negatively affected by nicotine exposure, but
surprisingly nicotine was shown to have a positive ef-
fect on the liver in the diet-induced obese animal model,
which should be confirmed by future research.
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1 Introduction
Alcohol, cannabinoids and nicotine are three major
drugs of abuse, widely used especially among the youth
(Johnston, O’Malley, Miech, Bachman & Schulenberg,
2017). It is important to study their effects, considering
that they are common causes of preventable morbidity
and mortality (Johnston et al., 2017). In this work, we
want to provide a concise summary of the complex ef-
fects of alcohol, cannabinoids and nicotine on liver func-
tions (see Table 1). The liver is a major detoxifying and
drug metabolizing organ, with an enormous functional
reserve (Theise, 2013). It can be affected by a wide
range of therapeutic and environmental chemicals, dir-
ectly or by immune mechanisms (Theise, 2013).
Fatty liver disease (alcoholic or nonalcoholic) is a
broad term which includes three liver alterations that
can be present in any combination: hepatocellular ste-
atosis, steatohepatitis and steatohepatitis with fibrosis
(Theise, 2013). Hepatocellular steatosis or fat accu-
mulation can be microvesicular (small lipid droplets)
or macrovesicular (large lipid droplets) (Theise, 2013).
Steatohepatitis is characterized by hepatocyte balloon-
ing, Mallory-Denk bodies (eosinophilic cytoplasmic in-
clusions in degenerating hepatocytes) and inflammatory
infiltration (Theise, 2013; Mandrekar & Szabo, 2010).
Finally, steatohepatitis with fibrosis starts as central
vein sclerosis and the scarring gradually spreads to
the portal tracts forming central-portal or portal-portal
bridging fibrosis (Theise, 2013; Sakhuja, 2014). Then, if
the injury continues, the fibrosis and hepatocytes regen-
eration involves a pseudolobular or Laennec cirrhosis in
which a nodular morphology is present (Theise, 2013;
Sakhuja, 2014).
Among the inducers of liver diseases, alcohol is the
most important agent that produces toxic liver injury
and 60% of chronic liver disease in Western countries
is caused by excessive ethanol intake (Theise, 2013).
The Monitoring the future (MTF) survey conducted in
2016 shows that 61% of students have consumed alco-
hol by the end of high school and 46% of 12th graders
have reported being drunk at least once in their life,
which makes alcohol the most widely used substance
by today’s teenagers (Johnston et al., 2017). Alcohol
causes lipid metabolism changes, decreases export of
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lipoproteins, and causes cell injury, which manifest as
fatty liver disease (Theise, 2013). Hepatotoxicity of eth-
anol has been shown in experimental animals (Habib-
ur-Rehman, Tahir, Lone & Sami, 2011; Keegan, Mar-
tini & Batey, 1995; Tsuchishima et al., 2013). Habib-
ur-Rehman and co-workers (2011) treated albino rats
with ethanol for 8 weeks and found functional and
structural liver changes, such as increase in the serum
alanine aminotransferase (ALT) and gamma-glutamyl
transferase (GGT) levels, periportal inflammation, liver
weight and volume increase (Habib-ur-Rehman et al.,
2011). Another group induced alcoholic live injury by
delivering ethanol in the drinking water (Keegan et
al., 1995). They found evident hepatotoxic histological
changes (i.e., steatosis, inflammation, hepatocyte nec-
rosis and pericentral sclerosis) while maintaining a nu-
tritionally adequate food intake (Keegan et al., 1995).
In addition, ethanol consumption is one of the main
etiologic agents for hepatocellular carcinoma (The-
ise, 2013). For example, in the study conducted by
Tsuchishima and co-workers, male mice were admin-
istered ethanol through drinking water for 70 weeks
(Tsuchishima et al., 2013). 50% of those mice had sev-
eral larger nodules (5–22 mm) in their liver, histologic-
ally verified as trabecular HCC composed of eosinophilic
and vacuolated cells (Tsuchishima et al., 2013) (see Fig-
ure 1). The authors conclude that the tumorogenesis
could occur as a result of proto-oncogenes and/or onco-
suppressor genes mutations, due to repeated regenera-
tion processes, although further studies are necessary
(Tsuchishima et al., 2013).
Figure 1: Stereoscopic images of the liver tissue of ethanol ad-
ministered mice at weeks 60 and 70. (A) Control group (60 W): no
tumor. (B) Ethanol group (60 W): hepatic tumor was observed.
(C) Ethanol group (70 W): large hepatic tumor measuring 22 mm
was present. Adapted from Tsuchishima et al. (2013).
Together with alcohol, marijuana, made from leaves
of the Cannabis sativa plant, is the most widely used
illegal drug (Kumar, Abbas & Aster, 2013) and it is
a popular drug of choice among young people which is
mainly due to its easy availability and low cost. The
MTF survey shows that one in seventeen 12th grades
smoke marijuana daily (Johnston et al., 2017). Pinto
and co-workers showed that ∆-tetrahydrocannabinoid
(∆9-THC), marijuana’s most psychoactive cannabinoid,
does not produce any harmful effects on the liver of
healthy mice, when chronically administrated (Pinto,
Moura, Serra˜o, Martins & Vieira-Coelho, 2010). Mice
were given intraperitoneal injections of ∆9-THC, in a
total daily dose of 10 mg/kg body weight, for 10 days
and this treatment did not produce any significant
changes in the hepatic redox state (Pinto et al., 2010).
An increased expression of cannabinoid receptors type
1 (CB1) in human cirrhotic liver samples has been ob-
served and it has been shown that CB1 signalling has a
profibrogenic effect (see Parfieniuk & Flisiak, 2008). Ju-
lien and co-workers showed that cannabinoid receptors
type 2 are expressed in cirrhotic human liver, predom-
inantly in hepatic fibrogenic cells, but not in normal
liver, and when activated endogenously they counteract
liver fibrogenesis (Julien et al., 2005). Cannabidiol, the
major non-psychotropic cannabis component, amelior-
ates ischemia/reperfusion-induced liver damage (Fouad
& Jresat, 2011). Indeed, cannabidiol treatment resulted
in significant reduction of ischemia/reperfusion-induced
elevations of tumour necrosis factor-α and nitric ox-
ide in liver homogenates, as well as the serum level of
ALT (Fouad & Jresat, 2011). Furthermore, the hepato-
protective effect of cannabidiol was also shown on the
histopathological examination, where the histological
picture of the ischemia/reperfusion cannabidiol-treated
group was comparable to the control group (Fouad &
Jresat, 2011). Yang and co-workers showed that canna-
bidiol protects mouse liver from acute alcohol-induced
steatosis (Yang et al., 2014). Cannabidiol preven-
ted ethanol-induced serum aspartate aminotransferase
(AST) increase and significantly attenuated the hepatic
triglycerides elevation (Yang et al., 2014) (see Figure
2). Furthermore, cannabidiol lowered basal triglycerides
levels and completely reversed the ethanol-induced de-
cline in hepatic ATP levels (Yang et al., 2014).
Cigarette smoking represents another factor that in-
creases risk or susceptibility for a lot of diseases and for
liver disease as well. In particular, cigarette smoking
by teenagers and young adults leads to immediate and
serious health problems including respiratory and non-
respiratory effects, addiction to nicotine, and the as-
sociated risk of other drug use. Several studies have
found nicotine to be addictive in ways similar to heroin,
cocaine, and alcohol. In fact, nicotine is a highly ad-
dictive alkaloid, found in tobacco leaves, responsible for
the acute effects of smoking (i.e., increased heart rate,
blood pressure, cardiac contractility and output) (Ku-
mar et al., 2013). Thirty-day prevalence of cigarette
use, for 12th graders, was 11% in 2016 (Johnston et al.,
2017).
It is continuously declining from 1997 (37%), due to
increases in disapproval and perceived risk (Johnston
et al., 2017). A retrospective follow-up study of a 10-
year interval was conducted on a total of 3,365 sub-
10.7423/XJENZA.2017.2.05 www.xjenza.org
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Figure 2: (A) H&E staining and (B) oil red O staining showing increased lipid accumulation in mouse liver after binge alcohol
treatment. CBD decreases this lipid accumulation (image 4 compared to image 3 in (A) and (B)). Adopted from Yang et al. (2014).
jects, to assess the effect of cigarette smoking on the
development or cure of nonalcoholic fatty liver disease
(Hamabe et al., 2011). This study showed that cigarette
smoking is an independent risk factor for nonalcoholic
fatty liver disease development (Hamabe et al., 2011).
Jensen and co-workers (2013) showed that chronic nicot-
ine exposure induces a significant increase in ALT, AST
and alkaline phosphatase (ALP) levels in rats, as well
as an increase of biliary proliferation and fibrosis, which
may play a role in the pathogenesis of cholangiopath-
ies (Jensen et al., 2013) (see Figure 3). On the other
hand, an interesting study was conducted by Seoane-
Collazo and co-workers (Seoane-Collazo et al., 2014).
They found that nicotine reduced liver steatosis, in-
flammation and ER stress in diet-induced obese male
rats (Seoane-Collazo et al., 2014). Moreover, this ef-
fect was produced independently of nicotine’s anorectic
action (Seoane-Collazo et al., 2014). Finally, Lu and
co-workers (2013) showed that nicotine treatment alone
does not induce a necro-inflammatory response nor ste-
atosis, while it enhances ethanol-induced steatosis (Lu,
Ward & Cederbaum, 2013). In addition, nicotine and
ethanol when given alone increase hepatic contents of
collagen type I and this effect is enhanced by a nicotine
and ethanol combination (Lu et al., 2013).
2 Conclusion
In conclusion, ethanol treatment deteriorates liver’s
function which can lead to cancer development. Nicot-
ine exposure was shown to induce liver injury and to
promote fibrosis, while its positive effect in diet-induced
obese animal models should be evaluated by further
research. Regarding cannabinoids, ∆9-THC was not
Figure 3: Evaluation of collagen deposition by Masson’s tri-
chrome staining in liver sections from control and nicotine-treated
rats. Masson’s trichrome staining in control (A) and nicotine-
treated rats (B). Chronic administration of nicotine stimulated an
increase in collagen deposition (blue staining) around the portal
areas of nicotine-treated (B) compared with normal control rats
(A). Bile ducts are indicated with yellow arrows. Adapted from
Jensen et al. (2013).
shown to produce any harmful effects on the liver,
while cannabidiol showed hepatoprotective effects in
ischemia/reperfusion and alcohol-induced liver injuries.
Therefore, cannabinoid signalling modulation could po-
tentially be a new therapeutic approach in the liver
fibrosis management.
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